ArticleHaematologica2016
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.
Abstract readLetterMulticenter Study
In one paragraph
Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.Blood advances · 2020Trial
- Predicting response to hypomethylating agents in myeloid neoplasms: a robust model.Annals of hematology · 2026Article
- P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.Science advances · 2026Article
- Significance of targeting DNMT3A mutations in AML.Annals of hematology · 2025Review
- Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes.International journal of molecular sciences · 2024Article
- Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine-A Retrospective Analysis.Cancers · 2024Article
- Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia.Targeted oncology · 2024Article
- Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway.JCI insight · 2023Article
- miR-196b-TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Article
- Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives.Cancers · 2021Review
- Oridonin inhibits DNMT3A R882 mutation-driven clonal hematopoiesis and leukemia by inducing apoptosis and necroptosis.Cell death discovery · 2021Article
- Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.Blood advances · 2021Article
- Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.Blood advances · 2021Article
- Alterations toCancer research · 2021Review
- Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia.Cancer drug resistance (Alhambra, Calif.) · 2021Article
- DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.Leukemia research · 2020Article
- A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.Blood advances · 2020Article
- Clinical update on hypomethylating agents.International journal of hematology · 2019Review
- Getting personal with myelodysplastic syndromes: is now the right time?Expert review of hematology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Catherine C CoombsMemorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, New York, NY, USA.
David A SallmanH. Lee Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, FL, USA.
Sean M DevlinMemorial Sloan Kettering Cancer Center, Department of Epidemiology & Biostatistics, New York, NY, USA.
Shweta DixitMemorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, NY, USA.
Abhinita MohantyMemorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, USA.
Kristina KnappMemorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, NY, USA.
Najla H Al AliH. Lee Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, FL, USA.
Jeffrey E LancetH. Lee Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, FL, USA.
Alan F ListH. Lee Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, FL, USA.
Rami S KomrokjiH. Lee Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, FL, USA.
Eric PadronH. Lee Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, FL, USA.
Maria E ArcilaMemorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, USA.
Virginia M KlimekMemorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, New York, NY, USA.
Marcel R M van den BrinkMemorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY, USA.
Martin S TallmanMemorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, New York, NY, USA.
Ross L LevineMemorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, New York, NY, USA.
Raajit K RampalMemorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, New York, NY, USA rampalr@mskcc.org.
Franck RapaportMemorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, New York, NY, USA.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MLCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., KISSELA, BRETT M · 2015 to 2024
$37.5MRole of TET2 mutations in malignant transformation and acute myeloid leukemiaR01CA173636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2013 to 2022
$6.3MECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTERU10CA180827 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI LEVINE, ROSS L, MELNICK, ARI M. · 2014 to 2018
$3.0MGenetic Dissection of Acute Myeloid Leukemia.R01CA169784 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2014 to 2018
$1.8MGenomic profiling and development of murine models of transformation of MPNsK08CA188529 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RAMPAL, RAAJIT · 2014 to 2018
$891kNCATS NIH HHS UL1 TR001425NCI NIH HHS K08 CA188529NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA169784NCI NIH HHS R01 CA173636NCI NIH HHS U10 CA180827
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAntimetabolites, AntineoplasticDNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA Methyltransferase 3AHumansLeukemia, Myeloid, AcuteMutation RateAntimetabolites, AntineoplasticDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.